.png){kind=icon}
.png){kind=icon}
Return
Cordycepin inhibits pancreatic cancer progression and enhances gemcitabine sensitivity by targeting the CDK2/E2F2 axis to modulate TNNI2 expression
.png){kind=icon}
OA
AI
R
Y
W
W
DOI：10.1016/j.bcp.2026.118299.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Cordycepin, a natural nucleoside analogue, exhibits anti-inflammatory and antitumor activity in multiple malignancies. However, the molecular basis of its action in pancreatic cancer and its potential role in chemosensitization remain incompletely defined. In this study, the effects of cordycepin on malignant phenotypes of pancreatic cancer cells were investigated in vitro. Network pharmacology was applied to identify candidate targets and construct a disease-drug-target-pathway network. Reverse virtual screening and molecular docking were used to predict key binding proteins, while RNA sequencing identified downstream pathways regulated by cordycepin. Target engagement was validated using cellular thermal shift assays, molecular docking, and molecular dynamics simulations. The underlying mechanistic pathways were further confirmed by functional experiments, and the therapeutic efficacy of cordycepin in combination with gemcitabine was evaluated. Our results demonstrated that cordycepin reduced the growth of pancreatic cancer cells and induced G2/M phase arrest and apoptosis. Network pharmacology identified 56 hub targets enriched in oncogenic pathways, including PI3K/AKT pathway. Reverse virtual screening revealed 111 candidate binding proteins, and intersection with hub targets highlighted five key effectors: CDK2, GSK3B, IL2, NOS3, and PARP1. Transcriptomic profiling showed marked disruption of cell cycle pathways, and CDK2 was validated as a direct molecular target of cordycepin. Cordycepin suppressed TNNI2 transcription by inhibiting the CDK2/E2F2 axis. Furthermore, cordycepin acted synergistically with gemcitabine to enhance antitumor responses and promote apoptosis in pancreatic cancer models. Collectively, cordycepin exerts antitumor activity in pancreatic cancer by targeting the CDK2/E2F2 axis to suppress malignant progression and by concurrently sensitizing cells to gemcitabine, thus holding promise as a therapeutic agent.
Keywords:
PC
Pancreatic Cancer
OS
Overall Survival
TCM
Traditional Chinese Medicine
HPDE
Human pancreatic ductal epithelial
DMSO
Dimethyl sulfoxide
CV
Crystal Violet
qRT–PCR
Quantitative Real-Time Polymerase Chain Reaction
WB
Western Blotting
CETSA
Cellular Thermal Shift Assay
ChIP
Chromatin Immunoprecipitation
GSEA
Gene Set Enrichment Analysis
PPI
Protein–Protein Interaction
GO
Gene Ontology
BP
Biological Process
CC
Cellular Component
MF
Molecular Function
TCGA
The Cancer Genome Atlas
GTEx
Genotype‒Tissue Expression
ROC
Receiver Operating Characteristic
sc-PDB
screening-ready Protein Data Bank
MD
Molecular Dynamics
HE
Hematoxylin and Eosin
IHC
Immunohistochemistry
DEGs
Differentially Expressed Genes
Pancreatic cancer
Natural compounds
Cordycepin
Gemcitabine
Drug combination therapy
Journal
IF:
5.6
Papers:
1.3W
Citations:
3.3W
Organization
Cited Papers